Health ❯ Healthcare ❯ Pharmacology
Combination Therapy Clinical Trials Targeted Therapies Natural Compounds Cancer Therapies Baxdrostat GLP-1 Receptor Agonists Therapeutics Ambroxol BTK Inhibitors Clinical Efficacy Trastuzumab Deruxtecan CAR T Cell Therapy Lithium Compounds Amyloid-targeting Therapies Antibody-Drug Conjugates Cancer Treatment Therapeutic Targets Corticosteroids Brepocitinib Cannabinoid Therapy Levetiracetam Orforglipron Acoramidis Pilocarpine-Diclofenac Eye Drops PARP Inhibitors Anti-Amyloid Drugs Olezarsen Selective Estrogen Receptor Degraders Repurposed Medications Fenfluramine Eye Drops Dapagliflozin HIF-2α Inhibitors IDO1 Inhibitors Small Molecules In Silico Methods Repurposing Existing Medications RNA Markers Quintuple Agonists Targeting Bacterial Resistance Belantamab Mafodotin Pharmacological Chaperones TYK2-JAK1 Inhibitors Repurposed Drugs LCL768 Bezuclastinib Targeted Therapy Cardiac Myosin Inhibitors NRF2 Inhibitors β2 Agonists Bruton Tyrosine Kinase (BTK) Inhibitors Inhaled Heparin Topical Therapies Belzutifan Bruton’s Tyrosine Kinase Inhibitors Oral Therapies Inhaled Therapies Cancer Therapy Ianalumab CETP Inhibitors TYK2 Inhibitors Malaria Treatments Denosumab Galectin-1 Inhibitors Anticancer Drugs Plant-based Therapies Pirtobrutinib Aldosterone Blockers Elinzanetant JAK Inhibitors Eli Lilly Anesthetic Agents Oral Medications Clinical Efficacy of Myosin Inhibitors Motion Sickness Alpelisib Aldosterone Synthase Inhibitors
The approach could open protein therapeutics to hard-to-drug cell-surface receptors by pairing computational design with high-throughput screening in native human cells.
